Close Menu

More articles about Molecular Diagnostics

The deal includes integrating an online ordering process for Ambry's genetic tests into Volpara's Aspen Breast software for medical practice management.

French startup SeqOne has adapted its sequencing data-analysis platform to support a new method for high-throughput processing of coronavirus tests in its home country.

A handful of recently published trials suggest that use of the pneumonia panel could lead to more targeted therapy delivered more quickly than standard methods.

The two organizations announced a partnership earlier this year to manufacture and process Curative's oral fluid-based SARS-CoV-2 test.

The DeepChek-HIV assays are designed for settings running either Sanger sequencing or next-generation sequencing workflows, according to the company.

The listing enables assay developers and testing labs in the US to access the instrument for COVID-19 testing, the firm said.

The firm also received the CE mark for the test, which uses a reformulated buffer and takes less time to process than a test requiring an RNA extraction step.

The new funds will be used, in part, to support ChromaCode's expansion into resource-limited communities in low- to middle-income nations.

The FDA granted Emergency Use Authorization for Everlywell's at-home nasal swab collection kit, which can be used with Fulgent and Assurance's tests.

The acquisition will round out BD's molecular portfolio and be complementary to the firm's Veritor immunoassay system, according to executives. 

The PCR-based test works with upper and lower respiratory specimens, including nasal swabs and sputum, and can be performed by high complexity labs.

The Cedars-Sinai Medical Center SARS-CoV-2 RT-PCR assay uses the A*Star Fortitude Kit 2.0 for the detection of SAR-CoV-2 specific RNA in nasopharyngeal swab samples.

Several groups are developing diagnostic viral genome sequencing assays and panels, which promise high sensitivity and additional information on viral origin and spread.

A recent study from New York University found Abbott's ID Now rapid point-of-care test could return false negative results.

The firm said it has begun distributing the Aptima SARS-CoV-2 test and expects to produce an average of 1 million per week.

Since the Salt Lake City-based company launched its SARS-CoV-2 test in March, it has recorded COVID-19-related test and equipment sales of over $18 million.

DNAe said its semiconductor-based platform has potential to detect a broader variety of pathogens and resistance genes than current molecular technologies.

The agreement marks Veracyte's first deal to expand the testing menu on the nCounter instrument since it acquired the rights to the platform from NanoString in December.

Novacyt said that the growing demand for its SARS-CoV-2 test, which was launched in late January, has significantly exceeded its expectations.

The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.

Pages

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.